Browse Articles

Discover research articles across all indexed journals

Efficacy and safety of fexagratinib (Fexa) in Chinese patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) harboring FGF receptor (FGFR) genetic alterations.

Journal of Clinical Oncology Xiaojie Bian, Shanshan Wang, Dingwei Ye et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.790

790 Background: Fexagratinib (former AZD4547), a selective and potent oral inhibitor of FGFR1-3, has shown promising efficacy and safety in phase I trials among solid tumor pts with FGFR1-3 alterations, including mUC. This study (NCT05086666) aimed to assess efficacy and safety of Fexa in previously treated Chinese mUC pts with FGFR alterations. Methods: Pts with mUC harboring FGFR3 alterations (including activating mutations or fusion detected via NGS panel) who failed at least 1 prior therapy or were platinum- ineligible, were enrolled. Pts received continuous oral Fexa 80mg BID until disease progression or unacceptable toxicity occurred. The primary endpoint was objective response rate (ORR) assessed by independent review committee (IRC) per RECIST v1.1. Results: As of data cutoff (14 Jun 2024), a total of 35 pts were enrolled, of those 80% were male with a median age of 66 years (range 41-86). Most pts (85.7%) had ECOG PS≤1, 43% had a creatinine clearance <60 mL/min, 66% had received ≥ 1 prior therapies, 66% had been treated with PD-(L)1. The primary tumor site was reported in the upper tract in 40% of pts, and 25.7% had liver metastases. The best overall responses assessed by IRC was 34.4% (95% CI, 18.6%-53.2%) in 32 evaluable pts, including 9 confirmed partial responses (cPRs), 2 unconfirmed PRs. Ten (37.0%) of 27 evaluable pts harboring FGFR3 mutation achieved at least one PR. Among 15 pts who experienced progression after PD-(L)1 treatment, 5 pts (33.3%) achieved cPRs. Median PFS by IRC was 3.6 (2.8, 6.1) months. Most common treatment-related adverse events (TRAEs) were anemia (40.0%), nail disorder (40.0%), hyperphosphatemia (37.1%) and hyponatremia (34.3%). Grade ≥3 TRAEs were reported in 54.3% of the pts, incidence >5% included pneumonia(5.7%), anemia (5.7%) and hand-foot syndrome (5.7%). Conclusions: Fexa was generally well tolerated in previously treated Chinese mUC pts, with no new safety signals identified. The efficacy observed was consistent with that previously reported in western populations, with notable benefits seen in pts with FGFR alterations who had experienced disease progression following PD-(L)1 treatment. Clinical trial information: NCT05086666 .

PRO-XL: A phase II study of zanzalintinib (XL092) in patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on lutetium-177 (177Lu)-PSMA-617.

Journal of Clinical Oncology Umang Swami, Kenneth M Boucher, Yeonjung Jo et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps285

TPS285 Background: 177Lu-PSMA-617 has been approved for patients with prostate-specific membrane antigen (PSMA)-positive mCRPC who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy after demonstrating improvement in overall survival (OS) in the phase III VISION trial (PMID: 34161051). However, the tumor eventually develops resistance to 177Lu-PSMA-617 and progresses, and therefore, therapies are needed to treat 177Lu-PSMA-617 refractory mCRPC. Prior studies have demonstrated a significant VEGF expression in LNCaP tumors and locally recurrent prostate cancer after radiotherapy. Also, tumor recurrence largely depends on new vessel formation through angiogenesis when radiation inhibits angiogenesis. Zanzalintinib is a novel, potent, orally bioavailable small molecule multi-targeted inhibitor of kinases, including the receptor tyrosine kinases (RTKs), VEGFR2, MET, and TAM kinases AXL, and MER, which have been shown to be overexpressed in radiation-resistant tumors. Therefore, zanzalintinib is expected not only to inhibit tumor angiogenesis but also to mitigate resistance to antiangiogenic therapy over time. We initiated a phase 2 trial of zanzalintinib in pts with mCRPC after progression on 177Lu-PSMA-617. Methods: This IRB-approved, investigator-initiated, single-arm, single-center, non-randomized, open-label study will enroll 30 patients. Zanzalintinib will be administered orally at 100 mg once daily. Eligibility criteria: ≥ 18 years of age, mCRPC with histologically/cytologically confirmed adenocarcinoma without small cell histology, progression on or after prior treatment with 177Lu-PSMA-617, ECOG performance status ≤ 2, and adequate organ function. Any number of prior therapies will be allowed. Primary Endpoint: Proportion of participants with non-progressive disease at 16 weeks of treatment with zanzalintinib as assessed by Prostate Cancer Working Group 3 (PCWG3)-modified RECIST v1.1. Thirty patients will ensure that the disease control rate can be estimated via a 95% confidence interval with a margin of error <0.20. Secondary Endpoints: safety, tolerability, PSA 50% response rate, and OS. Tissue and blood samples will be collected for correlative studies. Clinical trial information: NCT06568562 .

Germline DNA repair gene variants in patients under active surveillance for low-grade bladder cancer: Implications for risk stratification.

Journal of Clinical Oncology Roberto Contieri, Hurle Rodolfo, Giovanni Lughezzani et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.849

849 Background: The growing interest in de-intensifying therapeutic strategies for low-grade bladder cancer (BC), including active surveillance (AS), highlights the imperative need for precise patient stratification criteria. The major clinical challenge is the identification of patients at risk for progression to high-grade disease. To address this unmet need, we investigated the role of germline pathogenic variants (PVs) and variants of unknown significance (VUS) in DNA repair genes (DRG) to refine patient selection for AS. Methods: This ongoing prospective study includes patients with bladder cancer who have been enrolled in an AS protocol for a minimum of 12 months. Whole-exome sequencing was performed to screen for PVs and VUS in DRG (including TM, ATR, MRE11A, BAP1, BARD1, BRCA1, NBN, BRCA2, PALB2, BRIP1, CHEK2, RAD51C, FAM175A, RAD51D, GEN1, XRCC1, and the mismatch repair genes MLH1, PMS2, MSH2, and MSH6). The inclusion criteria for AS include suspicious recurrence at follow-up cystoscopy following a histopathologically confirmed diagnosis of low-grade pTa/pT1a NMIBC, with a maximum of five suspicious lesions, each no larger than 1 cm in diameter, absence of gross hematuria, and negative urinary cytology (UC). The primary endpoint was to describe the prevalence of PVs and VUS in AS patients. Patients with high-grade NMIBC and muscle-invasive bladder cancer (MIBC) were included as positive controls and screened for the same set of genes. This study is funded by the Associazione Italiana per la Ricerca sul Cancro (AIRC) under Protocol ICH-2812, code IG 2020-ID-25027. Results: From January to June 2024, a total of 15 patients under AS were tested. The median duration of surveillance at the time of testing was 16 months. All patients had a history of low-grade bladder cancer, with a median interval of 23 months between initial diagnosis and entry into the active surveillance protocol. None of the patients in the AS cohort harbored pathogenic variants in the targeted genes analyzed. In the positive control group, consisting of 10 patients with HG-NMIBC and 16 with MIBC, a total of 18 variants were identified, including 17 VUS and 1 PV. The distribution of variants was as follows: ATM (N=4), ATR (N=3), BARD1 (N=3), PMS2 (N=2), with one variant each in BRCA2, MSH6, NBN, PALB2, and GEN1. The single risk variant was detected in the CHEK2 gene. Conclusions: Our study indicates that none of the patients under AS with NMIBC harbored PVs or VUS the targeted genes. On the contrary, in the positive control group (NMIBC and MIBC), multiple VUS and one risk variant were identified, suggesting that germline DNA repair gene analysis may be more relevant in higher-risk bladder cancer cohorts. These findings underscore the need for further investigation into the utility of genetic screening, which might play a crucial role in refining patient selection for AS protocols in the future.

A real-world clinicogenomic study of androgen receptor mutations and co-mutations in prostate cancer: Clinical implications.

Journal of Clinical Oncology Emma G. Sturgill, Daniel J. Luckett, Tarun Agrawal et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.73

73 Background: While most prostate cancer (PCa) patients (pts) initially respond to androgen deprivation therapy, resistance commonly develops, resulting in castration-resistant PCa. In certain patients, androgen receptor ( AR ) mutations permit tumor cells to proliferate despite the absence of circulating androgens. This study leverages real-world clinicogenomic data to investigate the prevalence and clinical implications of AR mutations and co-mutations. Methods: We analyzed 3,753 pt records with PCa who underwent next-generation sequencing (NGS) from January 1, 2014 to October 1, 2024. NGS was ordered by >400 physicians from >180 community-based oncology clinics across the Sarah Cannon Research Institute network, and results were collated with pt medical records in the software platform, Genospace. Pts were stratified into AR -mutated ( AR m; 306 pts), AR -amplified ( AR amp; 231 pts), and AR wild-type ( AR WT; 3,216 pts) cohorts. Pts with multiple primary cancers were excluded. Results: AR mutations were detected in 306 pts (8%), with a higher detection rate in plasma- versus tissue-based NGS (15% vs 2%; p<0.01). AR mutations were more common in older pts, with 68% of AR m pts >70 years old compared to 53% of AR WT pts (p<0.01). The most common AR mutations included L702H (51%, 156 pts), T878A (38%, 115 pts), H875Y (23%, 70 pts) and W742C (8%, 25 pts), and over half of AR m pts reported multiple AR mutations (51%, 156 pts). Several genes were more frequently mutated in AR m versus AR WT pts, including TP53 (43% vs 32%), PTEN (10% vs 6%), BRCA2 (9% vs 4%), RB1 (5% vs 2%), and BRCA1 (4% vs 1%; p<0.01 for all). AR m pts reported a higher frequency of microsatellite instability (MSI) compared to AR WT pts (11% vs 2%; p<0.01). Within the AR m cohort, MSI was more frequently detected by tissue- versus plasma-based NGS (26% vs 7%; p<0.01). Specific AR mutations were enriched in MSI versus microsatellite stable (MSS) pts, including H875Y (50% vs 20%) and V716M (31% vs 2%; p<0.01 for both). Additionally, BRCA1/2 mutations were more common in AR m/MSI pts versus AR m/MSS pts ( BRCA1 : 15% vs 3%; BRCA2 : 35% vs 6%; p<0.01 for both). Pts in both the AR m (3.3 yrs) and AR amp (2.1 yrs) cohorts exhibited shorter overall survival from metastatic staging compared to the AR WT cohort (9.0 yrs; p<0.01 for both). Neither specific AR mutations nor MSI status correlated with survival outcomes. Conclusions: AR mutations are frequently detected by plasma-based NGS in the real-world setting, possibly due to test selection at disease progression and/or sampling of tumor heterogeneity. However, plasma-based NGS may miss other critical alterations, such as MSI status. The high co-occurrence of MSI in AR -mutated PCa suggests potential for combination therapies involving immunotherapy and novel AR degraders. These findings emphasize the need for tissue- and plasma-based genomic profiling to guide therapeutic decisions and optimize treatment strategies for advanced PCa.

Low-frequency noise and DC I–V characterization of gamma-ray irradiation-induced degradation and trap behaviors in a-IGZO TFTs

Applied Physics Letters Hongseung Lee, Jaewook Yoo, Hyeonjun Song et al. Feb 10, 2025 DOI: 10.1063/5.0238211

This work reports the impact of gamma-ray (γ-ray) irradiation-induced degradation based on the trap behaviors in amorphous indium-gallium-zinc-oxide (a-IGZO) thin-film transistors. By employing multiple measurement configurations via low-frequency noise and direct current I–V characterization, we quantitatively investigated the energetic distribution of subgap density-of-states in the a-IGZO channel and the spatial distribution of oxide traps (Not) in the gate insulator, respectively. Also, the qualitative analysis was performed to determine the oxygen-related defects after γ-ray irradiation using x-ray photoelectron spectroscopy. Furthermore, the validity of our results was additionally confirmed by measuring the breakdown voltage and applying positive-bias stress to the fabricated devices exposed to radiation for accelerated tests.

Metarhizium mendonceae sp. nov.: An important biological control agent for insect pests

PLoS ONE Jayara Dayany da Costa Silva, Paulo Roberto Ramalho Silva, Solange Maria de França et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0310548

The Metarhizium anisopliae complex consists of 34 formally described phylogenetic species. Metarhizium anisopliae sensu lato has been used for decades in Brazil as a biological control agent for controlling spittlebugs in sugarcane plantations. We investigated the identities of the Metarhizium isolates used in mycoinsecticide formulations through multilocus phylogenetic analyses and morphological characterization for species delimitation. A well-supported clade containing only isolates from this study formed a sister group with species of M. anisopliae sensu stricto, which we described as a new taxon, M. mendonceae sp. nov. Isolates URM 8144 and URM 8145 are used in the formulation of various brands of biological insecticides; however, they have always been referred to as M. anisopliae. According to the antibiosis assay, all the isolates of this new species were able to colonize and kill Mahanarva spectabilis nymphs. Therefore, M. mendonceae has been used in the formulation of mycoinsecticides for several decades under the name M. anisopliae.

Profiling difenoconazole and flusilazole resistance, fitness penalty and phenotypic stability in Venturia inaequalis

Scientific Reports Syed Shoaib Mubashir, Zahoor A. Bhat, Mushtaq A. Bhat et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89536-6

The nature of progression on long term active surveillance for confirmed Gleason grade group 1 prostate cancer in the modern era.

Journal of Clinical Oncology Kevin Shee, Janet E Cowan, Lufan Wang et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.360

360 Background: Gleason Grade Group 1 (GG1), or Gleason 3+3, prostate cancer (PCa), are considered low-risk, and unlikely to lead to major adverse outcomes such as metastasis or PCa-specific mortality. However, initial diagnoses of GG1 can upgrade over time, and balancing the need for monitoring with concerns about overtreatment of GG1 has led to the emergence of active surveillance (AS) as the standard of care for GG1 PCa. There has been a recent controversy regarding whether the label of cancer should be removed from GG1 tumors; proponents argue that such a change would dramatically reduce patient anxiety and overtreatment of GG1 PCa, while detractors argue that this could lead to failure to follow such patients and a missed opportunity for cure in those who might benefit. We sought to describe the nature of progression of GG1 disease in the modern era for confirmed GG1 patients after multiparametric prostate MRI-targeted biopsy in a large, well-annotated AS cohort. Methods: The Urologic Outcomes Database (UODB) at the University of California San Francisco (UCSF) was queried for men with cT1-2N0/xM0/x, PSA <20ng/ml, GG1 PCa with ≤33% biopsy core positivity with a minimum of 2 biopsies on AS with at least one multiparametric prostate MRI-targeted biopsy. Clinicodemographic factors and pathology data at diagnosis and at subsequent biopsies were obtained. Outcomes were any upgrade (≥GG2), major upgrade (≥GG3), increase in percentage of positive cores to >33%, and progression to active treatment. Life-table estimates and Kaplan-Meier analyses were used to describe major outcomes variables. Results: 803 men met inclusion criteria. Median (IQR) follow-up for the cohort was 114 (75-157) months. CAPRA score at diagnosis was low risk and intermediate risk in 749 (93%) and 54 (7%) patients, respectively. Median (IQR) PSA at diagnosis, any upgrade, and major upgrade was 5.0 (3.8-6.7) ng/mL, 6.9 (4.5-9.9) ng/mL, and 7.8 (5.5-11.8) ng/mL, respectively. At 5 and 10 years, any upgrade rate was 28% and 61%, major upgrade rate was 5% and 17%, rate of increase in core positivity from ≤33% to >33% was 22% and 37%, and active treatment rate was 15% and 33%, respectively. Patients with both upgrade to GG2 and increased core positivity and major upgrade were more likely to progress to active treatment compared to patients with either upgrade to GG2 or increased core positivity alone (Log-rank p<0.01). Conclusions: Men with confirmed GG1 PCa on AS with at least one MRI-targeted biopsy have high rates of minor upgrade, moderate rates of increased core positivity and progression to active treatment, and low rates of major upgrade on subsequent biopsy, and are more likely to progress to treatment if they experience major upgrade or both upgrade to GG2 and increase in core positivity. These findings highlight heterogeneity of outcomes in patients with confirmed GG1 PCa in the modern era and highlights the critical need for continued monitoring with AS in such patients.

A phase 2/3 multicenter trial evaluating safety and efficacy of a new mucoadhesive gemcitabine suspension for ablation of upper tract urothelial carcinoma.

Journal of Clinical Oncology Marie-Pier St-Laurent, Veronika Schmitt, Martin Gleave et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps889

TPS889 Background: Patients with large, multifocal, or frequently recurrent low-grade (LG) upper tract urothelial carcinoma (UTUC) often require nephroureterectomy to effectively manage their disease, despite the low oncologic risk of progression. There is a need for safer, more effective nephron-sparing treatments. Intraluminal therapies are underdeveloped and limited by the short dwell time of drugs in the collecting system. Intravesical gemcitabine has shown efficacy and minimal toxicity in treating bladder urothelial carcinoma, suggesting a similar potential for UTUC. The investigational drug (ST-02) is a novel mucoadhesive gemcitabine suspension designed for pyelocaliceal instillation. It changes from a liquid to a mucoadhesive gel in the collecting system once in contact with water, thereby facilitating prolonged exposure to gemcitabine. This trial aims to demonstrate that intraluminal administration of ST-02 can effectively and safely ablate LG UTUC. Methods: This is a prospective, multicenter, single-arm, open-label phase II/III clinical trial (NCT06124976) designed to enroll 70 patients with biopsy-confirmed LG UTUC. The study employs a two-stage design with early stopping rules, where the trial will be halted if there are 8 or fewer complete responses (CR) among the first 30 participants (phase II). Eligible patients must have tumors measuring 5-15 mm at treatment initiation. ST-02 will be instilled via retrograde or antegrade catheterization weekly for 6 weeks. The primary endpoint is the CR rate, assessed by ureteroscopic evaluation 6 weeks after the last instillation. Maintenance therapy with ST-02 will be offered to participants with ongoing CR at 3, 6, 9, 12, and 15 months. Secondary objectives include evaluating the durability of CR at 12 months, objective response rates based on tumor size, event-free survival, and safety. The trial includes a safety lead-in phase with pharmacokinetic evaluation in the first 10 patients. An independent Data Monitoring Committee will oversee safety and efficacy assessments. Clinical trial information: NCT06124976 .

A multi-centre review of the use of adjuvant pembrolizumab for renal cell carcinoma.

Journal of Clinical Oncology Eleanor McCarthy, Alice Chadwick, Juan José Soto-Castillo et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.484

484 Background: In patients with increased risk of recurrence after surgical resection of renal cell carcinoma (RCC), adjuvant treatment with pembrolizumab has been shown to reduce recurrences and improve overall survival. This treatment is now offered as standard of care in England. In the KEYNOTE 564 trial 96.3% of patients who received pembrolizumab experienced at least one adverse event and 32.4% of patients experienced an adverse event of grade 3-5. 38.9% of trial patients discontinued treatment early; 21.3% due to adverse events and 10.5% due to disease recurrence. 7.4% of patients who were treated with pembrolizumab were treated with high dose systemic steroids (≥40mg prednisolone per day). Aims: To evaluate how real world data compares to the findings of KEYNOTE 564, in UK centres. Methods: This was a retrospective review of 182 patients treated with adjuvant pembrolizumab following surgery for RCC across 7 centres in the UK between 2022-2024. Toxicity, discontinuation, use of steroids, and recurrences were assessed. Results: 182 patients were started on adjuvant pembrolizumabbetween 2022-2024. Median FU is 8.4 months. Overall, 18 patients (9.9%) have experienced recurrence, and 15 (83.3%) of these occurred during treatment. 82 (45.1%) patients are currently undergoing treatment, and 41 (22.5%) patients completed the full 12-month course. 59 (32.4%) patients did not complete the full course, 44 (24.1%) due to toxicity and 15 (8.2%) due to recurrence. Mean number of cycles completed for patients discontinuing treatment was 3.4 (range 1 – 8). Toxicity was varied with endocrine (24%), skin (23%) & colitis (12%) being the most common toxicities of all grades. 24 (13.2%) and 3 (1.6%) patients experienced grade 3 and grade 4 toxicities respectively. The commonest toxicity leading to treatment discontinuation was colitis (27.3%). The number of patients requiring steroids for toxicity management was 59 (32.4%) with 34 (18.6%) requiring high dose steroids and 7 (3.8%) requiring additional immunosuppressive agents (methotrexate (3), infliximab (3) and MMF (1)). 26 (14.2%) patients required hospitalisation for management of toxicity. There was 1 treatment-related death due to complications from colitis and nephritis. Conclusions: In our group of patients, discontinuations of Pembrolizumab due to toxicity and recurrence rates were similar to data from KEYNOTE 564. A larger proportion of patients in our real world data were treated with high dose steroids (19%) compared to the trial (7.4%).

TP53 Y220C mutations in advanced urothelial bladder cancer (UBC): A genomic landscape study.

Journal of Clinical Oncology Rosa Nadal, Joseph M Jacob, Gennady Bratslavsky et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.821

821 Background: TP53 is the most frequently altered gene in human cancers. Novel agents targeting the pathogenic TP53- Y220C mutation and p53-based cancer therapy have attracted significant interest. Evaluation of TP53- Y220C mutation and co-occurrent alterations in UBC is needed. Methods: FFPE tissue from 11,224 UBC patients (pts) underwent hybridization capture and comprehensive genomic profiling. A total of 324 cancer related genes including selected introns of 31 genes frequently rearranged in cancer were evaluated for genomic alterations (GA). We obtained an average sequencing depth of 650X. Microsatellite instability (MSI) status and tumor mutation burden (TMB) were estimated using next-generation sequencing. TMB-high was defined as ≥10 mutations/Mb. PD-L1 expression was measured by IHC (DAKO 22C3). Comparisons were performed using the χ 2 method with Yates correction. Results: TP53 Y220C mutation (Y220C+) was identified in 73 UBC (0.65%). Age/gender were comparable between TP53 Y220C negative (Y220C-) and TP53 Y220C+ pts; 8.4% of TP53 Y220C+ and 8.2% of TP53 Y220C- UBC cases exhibited ≥1 GA. In TP53 Y220C+ UBC, the frequency of co-occurring GA was significantly lower for FGFR3 (8.2% vs 18.3%; P = .038), MTAP loss (13.3% vs 25.1%; P = .035), CDKN2A (26% vs 37.8%; P = .05), and CDKN2B (19.2% vs 30.2%; P = .05) vs TP53 Y220C- UBC. BRCA1 GA was significantly higher in TP53 Y220C+ UBC (8.2% vs 2.0%; P < .0001). In TP53 Y220C+ UBC, trends were observed with numerically higher GA frequency in ERBB2 (20.5% vs 17.6%; not significant [NS]), RB1 (24.7% vs. 21.4%; NS) and numerically lower GA frequencies in TERT (61.1% vs 76.1%; NS), PIK3CA (15.1% vs 21.6%; NS). No significant differences in other GA frequencies: TSC1 (8.2% vs 9.0%, NS), ERBB3 (6.8% to 6.2%, NS), BRCA2 (4.1% to 3.2%, NS), FGFR2 (2.7% to 1.1%, NS), or in MSI / TMB status were detected between groups. PD-L1 low expression (1-49%) was observed in 7.3% of TP53 Y220C+ UBC. Conclusions: The TP53 Y220C mutation is rare in advanced UBC (< 1% of cases). In our study, this mutation was associated with specific co-occurring GA, notably with a significantly lower frequency of FGFR3 and higher BRCA1 GA. TP53 Y220C mutation warrants further clinical investigation in basket trials, including UBC, e.g. NCT04585750. TP53 Y220C+ UBCn=73 TP53 Y220C- UBCn=11,151 p value BRCA1 8.2% 2% <.0001 FGFR3 8.2% 18.3% .038 MTAP 13.3% 25.1% .035 CDKN2A 26% 37.8% .05 CDKN2B 19.2% 30.2% .05 MSI-high 0% 0.7% NS TMB-high 34.2% 34.1% NS

Direct measurement of thermal Knudsen forces in rarefied gas environments

Applied Physics Letters Greg I. Acosta, Amun Jarzembski, Mohammad Ghashami Feb 10, 2025 DOI: 10.1063/5.0250855

At micro- and nanoscales, momentum transfer between surfaces is influenced by various physical mechanisms, including quantum fluctuations, electromagnetic interactions, electric charges, and the dynamics of (rarefied) gases. Under non-isothermal conditions, rarefied gases give rise to thermal Knudsen forces whose magnitudes strongly depend on the gas species and surface characteristics. Knudsen forces are particularly relevant in nanotechnology, optical manipulation, and aerospace systems, where gas rarefaction occurs due to highly confined geometries, sub-micrometer length scales, and reduced particle densities. Despite their significance, predictive modeling of Knudsen forces is limited by a lack of comprehensive experimental data across diverse materials and surface morphologies. In this work, we present a highly sensitive and adaptable measurement platform capable of directly quantifying Knudsen forces using a suspended, interchangeable micro-cantilever within controlled rarefied helium and nitrogen environments. The system integrates optical fiber interferometry to precisely capture out-of-plane displacements at sub-micrometer resolution, driven by Knudsen forces. From the empirical data, we derive a robust correlation linking the magnitudes of Knudsen forces to energy accommodation coefficients, offering deeper insights into the underlying gas–surface interaction mechanisms.

Effects of outdoor play on body composition and physical performance in children: the Yamanashi Adjunct study of the Japan Environment and Children’s Study

PLoS ONE Masanori Wako, Taro Fujimaki, Jiro Ichikawa et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0317925

Introduction Childhood is a pivotal developmental stage that substantially affects lifelong habits. Recent research has emphasized the vital role of outdoor play in children’s mental and physical well-being. Despite the World Health Organization recommending 1 hour of daily physical activity for children, a knowledge gap exists regarding the specific link between children’s physical performance, body composition (evaluated through bioelectrical impedance analysis [BIA]), and outdoor play habits. Methods Utilizing data from the Japan Environment and Children’s Study, a national birth cohort study, this study included 494 eight-year-old participants. The assessment included body composition (height, weight, body fat percentage, predicted muscle weight, and phase angle using BIA) and physical performance (50 m sprint, standing long jump, 20 m shuttle run, and handgrip strength). Parents provided information on children’s outdoor playtime. Results The group with more outdoor play demonstrated superior sports test results, particularly among boys. Girls engaged in increased outdoor play exhibited higher predicted muscle weights, whereas boys showed greater phase angles in the lower limbs. Handgrip strength correlated with phase angle and predicted muscle weight. Notably, the association between body composition and sports test results was more pronounced in boys than in girls, with phase angles exhibiting stronger links to running and jumping. Conclusion This pioneering study explored the relationship between outdoor play, body composition, and physical performance in children. Outdoor play positively correlated with improved sports performance, revealing sex disparities in body composition changes. Unlike previous studies focusing on general physical development, this study scrutinized specific physical functions, uncovering correlations between phase angle and muscle quality. Findings suggest that outdoor play positively impacts muscle quality, especially in boys, contributing to enhanced physical performance in children. Understanding these effects on body composition and physical activity is imperative for promoting children’s health.

Analyzing the influence of manufactured sand and fly ash on concrete strength through experimental and machine learning methods

Scientific Reports S Sathvik, Solomon Oyebisi, Rakesh Kumar et al. Feb 10, 2025 DOI: 10.1038/s41598-025-88923-3

Abstract River sand supplies are decreasing due to overexploitation and illicit sand mining. One ton of Portland cement production (the main binder in concrete) emits about one ton of carbon dioxide into the atmosphere. Thus, this study replaced conventional cement and river sand (R sand) with recycled waste materials (fly ash and manufactured sand (M sand)). The concrete mix proportions were designed using M40 grade, and the Ordinary Portland cement (OPC) and R sand were replaced with 0–85 wt% of fly ash and 0-100 wt% of M sand. The concrete samples were tested for compressive strength after 3–90 days of curing. Furthermore, machine learning (ML) techniques were engaged to predict the compressive strength of the concrete samples using Extreme Gradient Boosting (XGBoost), Long Short-Term Memory (LSTM), Support Vector Machine (SVM), and Gaussian Process Regression (GPR). Besides, the concrete samples containing fly ash, M sand, and R sand were characterized for microstructures and elemental compositions using SEM-EDS. The results revealed improved concrete compressive strength by incorporating fly ash and M sand. After 28 days of curing, OPC and R sand were partially replaced with 25 and 50 wt% of fly ash and M sand attained the designed strength of M 40 grade concrete. XGBoost model yielded the most accurate performance metrics for forecasting the compressive strength in training and testing phases with R2 values equal to 0.9999 and 0.9964, respectively, compared to LSTM, SVM, and GPR. Thus, the XGBoost approach can be a viable technique for forecasting the strength of concrete incorporating fly ash and M sand. SEM-EDS analyses revealed compact formations with high calcium and silicon counts. Thus, the XGBoost approach can be a viable technique for forecasting the strength of concrete incorporating fly ash and M sand.

Avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) with or without diabetes mellitus (DM): Long-term outcomes from JAVELIN Bladder 100.

Journal of Clinical Oncology Shilpa Gupta, Petros Grivas, Se Hoon Park et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.869

869 Background: In the JAVELIN Bladder 100 phase 3 trial, avelumab 1LM + best supportive care (BSC) significantly prolonged overall survival (OS) and progression-free survival (PFS) vs BSC alone in pts with aUC that had not progressed with 1L platinum-based chemotherapy (PBC). In some cancers, the presence of DM has been associated with reduced efficacy of immunotherapy; however, data in UC are limited. We report post hoc exploratory analyses from JAVELIN Bladder 100 in pts with or without DM at randomization. Methods: Eligible pts with unresectable locally advanced or metastatic UC without progression after 1L PBC were randomized 1:1 to receive avelumab + BSC or BSC alone. The primary endpoint was OS measured from randomization; secondary endpoints included PFS measured from randomization and safety. Results: At randomization in the avelumab + BSC (n=350) and BSC alone (n=350) arms, 55 (15.7%) and 59 (16.9%) pts had documented controlled DM, and 295 and 291 pts did not have documented DM, respectively. Median follow-up in both arms was ≥38.0 months (data cutoff, June 4, 2021). In pts with or without DM, OS and PFS (investigator assessed) were prolonged with avelumab + BSC vs BSC alone (Table). In the safety analysis set of avelumab-treated pts with (n=54) or without (n=290) DM, respectively, treatment-related adverse events (AEs) of any grade occurred in 75.9% and 78.6% (grade ≥3 in 24.1% and 18.6%) and led to avelumab discontinuation in 9.3% and 12.1%; immune-related AEs of any grade occurred in 31.5% and 32.4%. Limitations include the exploratory nature of the analysis and the potential for missing DM diagnosis. Conclusions: In exploratory analyses, avelumab 1LM was associated with long-term efficacy and consistent safety in pts with aUC with or without DM. Clinical trial information: NCT02603432 . Pts with DM Pts without DM Avelumab + BSC (n=55) BSC alone (n=59) Avelumab + BSC (n=295) BSC alone (n=291) Median OS (95% CI), months 20.8 (18.0-32.4) 14.5 (11.7-21.3) 24.7 (19.9-30.0) 15.8 (13.3-18.7) 2-year OS (95% CI), % 44.5 (30.7-57.3) 34.1 (22.2-46.3) 50.7 (44.8-56.4) 39.4 (33.6-45.2) 3-year OS (95% CI), % 33.1 (20.4-46.4) 20.3 (10.8-31.9) 36.6 (30.6-42.6) 31.9 (26.3-37.7) Hazard ratio (95% CI) 0.60 (0.37-0.95) 0.78 (0.64-0.96) Median PFS (95% CI), months 5.6 (3.7-9.3) 2.0 (1.9-3.7) 5.4 (3.8-7.2) 2.1 (1.9-3.5) 2-year PFS (95% CI), % 18.5 (9.1-30.6) 9.2 (3.4-18.6) 24.3 (19.3-29.7) 6.5 (3.8-10.2) 3-year PFS (95% CI), % 13.5 (5.5-25.1) 5.5 (1.4-13.8) 16.3 (11.7-21.6) 5.3 (2.9-8.9) Hazard ratio (95% CI) 0.50 (0.33-0.77) 0.54 (0.45-0.65)

Tislelizumab in combination with abiraterone/enzalutamide for metastatic castration-resistant prostate cancer with intraductal adenocarcinoma of the prostate after progression on prior androgen receptor pathway inhibitor.

Journal of Clinical Oncology Qiyu Zhu, Jinge Zhao, Pengfei Shen et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps299

TPS299 Background: Intraductal adenocarcinoma of the prostate (IDC-P) serves as an aggressive pathological pattern of prostate cancer. Previous retrospective study suggested limited therapeutic response of chemotherapy and androgen depriving therapy for patients with IDC-P. No standard of care treatment options are established for this type of tumor. IDC-P was characterized by genomic instability, high homologous recombination repair (HRD) scores and mutational enrichment of mismatch repair (MMR) pathway, which are predictive for response to immune checkpoint inhibitor. Tislelizumab, an investigative anti-PD-1 antibody, has demonstrated disease stabilization capacity to multiple advanced tumors. Thus in this study, we aim to investigated the efficacy and safety of tislelizumab in combination with androgen receptor pathway inhibitor (ARPI) in metastatic castration-resistant prostate cancer patients (mCRPC) after failure of first-line novel hormone therapy regimens. Methods: This is a phase II, multisite, open label study with one cohort. Eligible patients must have pathologically confirmed IDC-P. Patients with any component of neuroendocrine tumor are ineligible. Patients must have received one prior type of novel hormone therapy (e.g., abiraterone, enzalutamide) in mCRPC stage . Patients receiving chemotherapy in the mCRPC stage are excluded. Participants will receive tislelizumab 200mg IV every 21 days in combination with ARPI change (abiraterone 1000 mg PO QD+ prednisone 5 mg PO BID/enzalutamide 160 mg PO QD) for four cycles. The primary endpoint is prostate specific antigen progression-free survival (PSA-PFS) and radiographic PFS (rPFS), with key secondary endpoints including PSA response and overall survival (OS). Exploratory objectives include analyzing DNA and RNA sequencing of tumors, and measurement of ctDNA and TMB. Clinical trial information: ChiCTR2400085267 .

Muscle invasive bladder cancer treatment selection in an emerging treatment era: A patient preference study.

Journal of Clinical Oncology Angela Smith, John L. Gore, Stephanie Chisolm et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.753

753 Background: Patients with muscle invasive bladder cancer (MIBC) face a preference-sensitive choice among various treatment alternatives. MIBC is typically treated with radical cystectomy (RC) or bladder-sparing chemoradiation, but systemic therapy also plays a conjunctive role in reducing recurrence rates. This study elicited preferences for available and emerging systemic treatments among MIBC patients in the United States. Methods: Patients with self-reported MIBC participated in an online survey. A discrete-choice experiment elicited preferences for attributes of existing and emerging systemic treatments that could be administered with either RC or bladder-sparing approaches. Evidence-based attributes (and levels) included timing and duration of therapy (3 months before and/or 9-12 months after primary treatment); time in delaying cancer recurrence (20-64 months); overall survival (OS) rate at 5 years (40%-85%); chance of treatment-related adverse events (AEs), including fatigue (from none to moderate-severe), neuropathy (from none to moderate-severe), and risk of immune-related AEs that require oral steroid treatment (0%-25%). Conditional relative importance of attributes and risk tolerance were calculated from random-parameters logit models. In addition, direct-elicitation questions offered choices between fixed profiles of bladder-sparing treatment and RC with adjuvant and neoadjuvant systemic treatments. The Shared Decision Making (SDM) Questionnaire (SDM-Q-9) was also included, revealing patients’ levels of satisfaction with previous real-world choices. Responses to the fixed-profile questions and SDM-Q-9 were analyzed descriptively. Results: 202 participants completed the survey. Of the treatment attributes and levels evaluated, improvements in efficacy were most important (OS at 5 years, followed by delaying cancer recurrence). The average patient was tolerant of AEs and willing to accept high levels of risks (greater than those presented in the survey) and severity for any of the OS improvements offered. Two-thirds of respondents (66.8%) preferred RC plus neo- and adjuvant intravenous treatment in a profile with a 25-percentage-point increase in OS at 5 years, a 40-month delay in recurrence, and a 15% risk of immune-related AEs, mild fatigue, and nerve damage over a bladder-preserving treatment with chemoradiation and no AEs. Almost 20% of respondents disagreed with the statement “My doctor asked me which treatment option I prefer” when reflecting on their SDM experiences. Conclusions: Improving OS and delaying recurrence were the most important attributes to patients in this sample, and patients were willing to accept clinically relevant treatment-related AEs for the improvements in efficacy. Patients demonstrated heterogeneous preferences; efforts to promote shared decision-making are therefore warranted.

Comprehensive proteomic profiling of plasma samples associated with response or resistance to immune checkpoint inhibitors (ICI) in patients with renal cell carcinoma (RCC).

Journal of Clinical Oncology Soki Kashima, Wenxin Xu, John Canniff et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.562

562 Background: ICI-based therapies are the cornerstone of treatment for advanced RCC. While many studies have focused on tumor-based biomarkers, circulating factors play an important role in therapeutic response. This study utilized a high dimensional proteomic platform to investigate plasma proteins from RCC patients undergoing ICI-based therapies to identify potential biomarkers associated with treatment outcomes. Methods: A total of 43 plasma samples (n = 40 clear cell; n = 3 non-clear cell) were collected from 33 advanced RCC patients, with 16 paired samples (pre- and post-treatment) from 6 patients and 27 unpaired samples. The cohort included patients treated with ICI monotherapy (n = 22), ICI + ICI (n = 13), ICI + VEGF inhibitors (n = 7), and ICI + CCR2/CCR5 antagonist (n = 1). For this study, we analyzed pre-treatment samples from responders (R) (n = 8; complete or partial responses), and non-responders (NR) (n = 4; progressive disease). We performed plasma proteomic analysis using the SomaScan 11k proteomic platform, and Mann-Whitney U-test comparisons between ICI-naïve samples of R and NR groups. We also performed a paired test between ICI-naïve and ICI-exposed samples in R (n = 3 patients with paired samples). Nominal p-values are reported. Results: All 43 samples passed quality control. In ICI-naïve samples, we observed that ICAM1 and ITIH3 levels were significantly higher in R compared to NR (p = 0.016 for both). Conversely, CILP2 and leptin were significantly elevated in NR (p = 0.016, p = 0.004, respectively). Further analysis for treatment evolution through paired samples showed that PD-1, CXCL9, and HLA-B were significantly elevated in ICI-exposed samples compared to ICI-naïve samples in R (p = 0.021, p = 0.022, p = 0.041, respectively). Conclusions: Our exploratory proteomic analysis identified higher ICAM1 and ITIH3 levels in ICI responders, which may reflect anti-tumor inflammation and the recruitment of immune cells to tumors. Elevated CILP2 and leptin levels were observed in ICI non-responders, highlighting their potential contributions to an immunosuppressive environment through Tregs and the TGF-β pathway. Beyond the potential biomarkers, the post-ICI elevation of CXCL9 and HLA-B in responders suggests that these may be linked to sustained immune activation during treatment, offering a foundation to understand treatment evolution in RCC.

Enhanced near-infrared photoresponse of SnS2 nanosheets by Er–Yb co-doping

Applied Physics Letters Lei Wang, Tengfei Huang, Ruipeng Hou et al. Feb 10, 2025 DOI: 10.1063/5.0249415

Rare earth (RE) ions are important dopants to modulate semiconductor properties because of their abundant energy levels. Herein, a simple Er–Yb co-doping strategy was developed to enhance the near-infrared optoelectronic properties of SnS2 nanosheets. The constructed device based on Er–Yb co-doping SnS2 has a detectivity of ∼4.97 × 108 Jones at 980 nm. The enhanced photoresponse of the doped system at 980 nm could be attributed to the upconversion behavior of the Er–Yb ion pairs. The Yb3+ ions as sensitizers significantly enhance the upconversion emission and near-infrared photoresponse properties of the material. The energy transfer from Yb3+ to Er3+ ions can occur between different layers of co-doping nanosheets by investigating the properties of the constructed SnS2:Er/SnS2:Yb homojunction nanosheets. Density functional theory calculations reveal that Er or Yb doping introduces slight structural and charge distribution changes owing to the similarity in the metal–atom coordination structure between SnS2 and RE sulfide. Our study demonstrates that RE doping is an effective way to improve the near-infrared photoresponse of 2D materials and clarifies the relationship between luminescence and photoelectric properties.

Flowing between gongs: Mixed-methods insights into shared flow and temporal distortion in music performance

PLoS ONE Hannah J. Gibbs, Andrea Schiavio Feb 10, 2025 DOI: 10.1371/journal.pone.0302769

Ideas of temporal distortion prevail in the discourse of flow research, where references are often made to “time flying”. Nonetheless, little research has investigated how flow affects time perception in terms of both directionality and surrounding context, particularly within shared flow. Simultaneously, temporal distortion during music listening has been explored, but little is known about how time is experienced by performers. With this in mind, we aimed to investigate whether time distortion is associated with the experience of shared flow state, and the awareness participants have towards influencing factors on such experiences, in the context of music performance. Four groups of Javanese gamelan ensembles (total N = 36, age in years M = 44.83, SD = 14.993, 47.2% female), played in three conditions. We collected qualitative and quantitative data; focus groups and follow-up surveys explored understandings of shared flow and time, while questionnaires included pre-validated scales and an item requiring participants to estimate how much time they thought had passed. Qualitative and mixed methods findings suggest an optimal middle ground of conditions for “time flying” to occur, akin to flow state. Meanwhile, quantitative results indicate a complex relationship between temporal distortion and shared flow, whereby the relationships are opposed under two shared flow factors.